EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

ResolvedStocks

Penumbra’s STORM-PE Trial Shows Superior Outcomes for CAVT Technology in Pulmonary Embolism

First Detected: Apr 14, 2026, 12:49 AM
Last Update: 5 months ago
5 articles·5 stories

Event Summary

The STORM-PE trial data showed that computer-assisted vacuum thrombectomy (CAVT) combined with anticoagulation resulted in significantly better functional outcomes compared to anticoagulation alone. After 90 days, patients treated with CAVT achieved greater walking distances and a higher proportion reached NYHA Class I (no physical limitations).

Timeline

LIXTE Biotechnology Reports Positive Clinical Data for Ovarian Cancer Treatment
Apr 14, 2026, 1:47 AMImpact: 6
Medtronic and Merit Medical Partner to Distribute ViaVerte Chronic Pain System
Apr 14, 2026, 1:38 AMImpact: 5
Microbot Medical Announces Full U.S. Market Release of LIBERTY Robotic System
Apr 14, 2026, 1:19 AMImpact: 6
Penumbra’s STORM-PE Trial Shows Superior Outcomes for CAVT Technology in Pulmonary Embolism
Apr 14, 2026, 12:48 AMImpact: 7

Price Impact

Since event start
PEN-3.01%